Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2022 Jan 11;25(4):713–719. doi: 10.1038/s41391-021-00484-4

Fig. 4. Clinical outcomes stratified by TP53 mutational status.

Fig. 4

Kaplan Meier Survival Curves of Oligo- and Polymetastatic (≤3) patients stratified by TP53 mutational status for radiographic progression-free survival (4a), time to castration resistant prostate cancer (4b), and overall survival (4c).